Results 1 to 10 of about 23,985 (238)

Oncolytic Virotherapy with Myxoma Virus [PDF]

Journal of Clinical Medicine, 2020
Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers. They selectively infect and kill cancer cells while sparing the normal counterparts, expose cancer- specific antigens and activate the host immune system against both viral and tumor determinants.
Diana Thomas, Grant Mcfadden, Masmudur Mohammed Rahman   +2 more
exaly   +3 more sources

Neutrophils in oncolytic virus immunotherapy. [PDF]

Front Immunol
Oncolytic viruses have emerged as a highly promising modality for cancer treatment due to their ability to replicate specifically within tumors, carry therapeutic genes, and modulate the immunosuppressive tumor microenvironment through various mechanisms. Additionally, they show potential synergy with immune checkpoint inhibitors.
Zhou D, Zhang C, Sun J, Yuan M.
europepmc   +4 more sources

Recent progress in combination therapy of oncolytic vaccinia virus

Frontiers in Immunology
In recent years, oncolytic viruses have emerged as promising agents for treating various cancers. An oncolytic virus is a non-pathogenic virus that, due to genetic manipulation, tends to replicate in and cause lysis of cancerous cells while leaving ...
Seyedeh Nasim Mirbahari, Seyedeh Nasim Mirbahari, Miles Da Silva, Miles Da Silva, Abril Ixchel Muñoz Zúñiga, Abril Ixchel Muñoz Zúñiga, Nika Kooshki Zamani, Nika Kooshki Zamani, Gabriel St-Laurent, Gabriel St-Laurent, Mehdi Totonchi, Taha Azad, Taha Azad   +12 more
doaj   +3 more sources

BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma [PDF]

Cell Reports Medicine
Summary: Long-term survival of glioblastoma multiforme (GBM) remains challenging, spurring the development of novel therapies such as oncolytic virus therapy.
Chen Guo, Zhilin Long, Peng Lin, Yinan Shen, Yiye Zhong, Jingjing Qian, Jichuan Yu, Weixi Zhao, Fuyi Liu, Yiling Ma, Jian Zheng, Jiayao Yang, Shuai Zhao, Xiaojuan Ran, Zhen Xia, Congying Wu, Yujia Cai, Chen Wang, Qi Xie   +18 more
doaj   +2 more sources

Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors [PDF]

Zhongguo aizheng zazhi, 2023
Treatment using oncolytic virus as a new tumor immunologic agent has made continuous breakthroughs in basic and clinical research of tumor in recent years, and it is expected to play an important role in cancer immunotherapy in the future.
Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association
doaj   +3 more sources

Oncolytic Virus Immunotherapy [PDF]

Cancers, 2021
Oncolytic viruses (OVs) were originally developed as direct cytotoxic agents but have been increasingly recognised as a form of immunotherapy [...]
Marchini, Antonio, Ilkow, Carolina S., Melcher, Alan   +2 more
openaire   +2 more sources

Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry

Nature Communications, 2021
Rat H-1 parvovirus (H-1PV) is in clinical development for oncolytic therapy. Here, Kulkarni et al. identify LAMC1 as a modulator of H-1PV cell attachment and entry and find that LAMC1 levels and H-1PV oncolytic activity correlate in 59 tested cancer cell
Amit Kulkarni, Tiago Ferreira, Clemens Bretscher, Annabel Grewenig, Nazim El-Andaloussi, Serena Bonifati, Tiina Marttila, Valérie Palissot, Jubayer A. Hossain, Francisco Azuaje, Hrvoje Miletic, Lars A. R. Ystaas, Anna Golebiewska, Simone P. Niclou, Ralf Roeth, Beate Niesler, Amélie Weiss, Laurent Brino, Antonio Marchini   +18 more
doaj   +1 more source

Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells

Viruses, 2022
Clinical studies in glioblastoma and pancreatic carcinoma patients strongly support the further development of H-1 protoparvovirus (H-1PV)-based anticancer therapies. The identification of cellular factors involved in the H-1PV life cycle may provide the
Tiago Ferreira, Amit Kulkarni, Clemens Bretscher, Petr V. Nazarov, Jubayer A. Hossain, Lars A. R. Ystaas, Hrvoje Miletic, Ralph Röth, Beate Niesler, Antonio Marchini   +9 more
doaj   +1 more source

The XVIII International Parvovirus Workshop Rimini, Italy, 14–17 June 2022

Viruses, 2023
The XVIII International Parvovirus Workshop took place in Rimini, Italy, from 14 to 17 June 2022 as an on-site event, continuing the series of meetings started in 1985 and continuously held every two years.
Giorgio Gallinella, Antonio Marchini
doaj   +1 more source

Measles Virus as an Oncolytic Immunotherapy [PDF]

Cancers, 2021
Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. Live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics. The versatile MeV reverse genetics systems allows for engineering of advanced targeted, armed, and shielded oncolytic viral vectors ...
Christine E. Engeland, Guy Ungerechts
openaire   +2 more sources